MDxHealth
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
30 mei 2007 - 08:17
Statutaire naam
MDxHealth
Titel
OncoMethylome’s Commercial Partner Veridex Licenses Prostate Cancer Methylation Technology to Laboratory Corporation of America® Holdings
Bericht
Liege (Belgium) – May 30, 2007, 8:00 am CET – OncoMethylome Sciences announced today that its commercial partner Veridex, LLC, granted a license to Laboratory Corporation of America® Holdings (LabCorp®) which permits LabCorp to commercialize nucleic acid testing technology for detecting the presence of a key tissue marker in prostate cancer, methylated GST-Pi.
The prostate cancer marker and methylation technology required to detect it were initially developed by OncoMethylome Sciences and were licensed to Veridex in a commercial deal that was announced on January 19, 2005. LabCorp is the first full-service, national clinical laboratory in the U.S. to access this important new technology. Terms of the agreement were not disclosed.
“I am pleased that this agreement between Veridex and LabCorp brings OncoMethylome methylation technology one step closer to commercialization” said Herman Spolders, CEO of OncoMethylome Sciences.
Gerelateerde downloads
Datum laatste update: 13 november 2024